Wenliang Tan Selected Research

Hepatocellular Carcinoma (Hepatoma)

3/2024	CircNUP54 promotes hepatocellular carcinoma progression via facilitating HuR cytoplasmic export and stabilizing BIRC3 mRNA.
2/2024	A novel risk score system based on immune subtypes for identifying optimal mRNA vaccination population in hepatocellular carcinoma.
1/2023	Identification of a Novel Ferroptosis-Related Gene Signature for Predicting Prognosis and Responsiveness to Immunotherapy in Hepatocellular Carcinoma.
1/2023	GPX2 is a potential therapeutic target to induce cell apoptosis in lenvatinib against hepatocellular carcinoma.
6/2022	Corrigendum to "TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma" [EBioMedicine 40 (2019) 446-456].
1/2022	CircLIFR suppresses hepatocellular carcinoma progression by sponging miR-624-5p and inactivating the GSK-3β/β-catenin signaling pathway.
1/2022	High Expression of Long Non-Coding RNA TMCO1-AS1 is Associated With Poor Prognosis of Hepatocellular Carcinoma.
1/2022	Identification of LSM Family Members as Novel Unfavorable Biomarkers in Hepatocellular Carcinoma.
1/2021	miR-126-3p contributes to sorafenib resistance in hepatocellular carcinoma via downregulating SPRED1.
12/2020	Erratum.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Wenliang Tan Research Topics

Disease

15	Neoplasms (Cancer) 03/2024 - 01/2017
15	Hepatocellular Carcinoma (Hepatoma) 03/2024 - 01/2017
4	Neoplasm Metastasis (Metastasis) 12/2020 - 01/2017
3	Carcinogenesis 03/2024 - 01/2018
1	Wounds and Injuries (Trauma) 01/2023
1	Hypertension (High Blood Pressure) 02/2022
1	Aortic Valve Stenosis (Aortic Stenosis) 02/2022
1	Syncope (Fainting) 02/2022
1	Alcoholism (Alcohol Abuse) 01/2021
1	Critical Illness (Critically Ill) 01/2021
1	Cholangiocarcinoma 01/2019
1	Uterine Cervical Neoplasms (Cancer of the Cervix) 12/2018

Drug/Important Bio-Agent (IBA)

5	Sorafenib (BAY 43-9006)FDA Link 06/2022 - 11/2017
4	Proteins (Proteins, Gene)FDA Link 01/2023 - 01/2018
3	Messenger RNA (mRNA)IBA 03/2024 - 01/2018
2	Circular RNAIBA 03/2024 - 01/2022
2	CateninsIBA 01/2022 - 01/2022
2	Long Noncoding RNAIBA 01/2022 - 12/2019
2	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 12/2020 - 01/2017
2	TNF Receptor-Associated Factor 4IBA 12/2020 - 01/2017
1	mRNA VaccinesIBA 02/2024
1	Malondialdehyde (Propanedial)IBA 01/2023
1	lenvatinibIBA 01/2023
1	Caspase 3 (Caspase-3)IBA 01/2023
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2023
1	Antihypertensive Agents (Antihypertensives)IBA 02/2022
1	Cyclin D1IBA 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	alpha-Fetoproteins (alpha-Fetoprotein)IBA 01/2022
1	ZincIBA 01/2022
1	Lactic Acid (Lactate)FDA LinkGeneric 01/2021
1	urinastatin (MR 20)IBA 02/2019
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2019
1	Sincalide FDA Link 12/2018
1	SB 3CT compoundIBA 11/2017

Therapy/Procedure

2	Therapeutics 01/2023 - 02/2019
1	Immunotherapy 01/2023
1	Lymph Node Excision (Lymph Node Dissection) 01/2019
1	Radiotherapy 12/2018